Measurement of SARS-CoV-2 antibodies in the study participants showed that 32% (113/300) of the study patients had COVID-19 IgG antibody, 12% (36/300) had COVID-19 IgM and 50.3% (151/300) had no COVID-19 IgM and IgG. This evidence concerns the gene CD40LG and COVID-19.